Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

ented PFS data, further define satraplatin's clinical profile as a potential second-line treatment option in metastatic HRPC.

In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed continue to be treated and all patients will be followed for overall survival. Overall survival data are expected to be available later this year. Pharmion expects to complete the Marketing Authorization Application (MAA) for satraplatin for Europe in the second quarter of 2007. GPC Biotech recently completed the New Drug Application (NDA) submission for satraplatin to the U.S. Food and Drug Administration (FDA).

Safety findings were consistent with previous clinical studies involving satraplatin. The most common adverse reactions consisted of myelosuppression (bone marrow functions): Twenty-one percent of patients in the satraplatin arm experienced grade 3 or 4 thrombocytopenia; 14 percent had leucopenia and 21 percent had neutropenia. Eight percent of patients in the satraplatin arm experienced grade 3 or 4 gastrointestinal toxicities, including nausea (1.3%), vomiting (1.6%), diarrhea (2.1%) and constipation (2.1%). Five percent or less of patients in the satraplatin arm experienced grade 3 or 4 fatigue, grade 3 or 4 infections and pulmonary/respiratory grade 3 or 4 toxicities.

About Prostate Cancer

Prostate cancer is the most common cancer among men in the U.S. and Europe. Approximately 219,000 men in the U.S. are expected to be diagnosed with the disease in 2007 and over 27,000 men are expected to die from the disease. In the European Union, over 200,000 new cases are expected to be diagnosed, and over 60,000 patients are expected to die each year. Since the incidence of prostate cancer increases with age, the aging of the overall population is expected to further increase the number of prostate cancer patients.

Most patients diagnosed with prostate cancer initially receiv
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. ... amended and increased its five-year revolving credit facility to ... an accordion feature that will allow the company to ... additional $30.0 million, subject to securing additional commitments from ... of the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
(Date:4/23/2015)... Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that ... on Thursday, May 7, 2015, after the close of ... audio webcast immediately following the announcement at 4:30 p.m. ... results and provide a business and financial update. ... via the Investors & Media section of the Jazz ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2
(Date:4/26/2015)... From March 18th, 2015 toward the ... Master™ Dahryn Trivedi, spent a month traveling in India ... institutions in the efforts of creating highly advanced, effective ... for human health care. , During their journey, ... institutions. All lab facilities are approved by the U.S. ...
(Date:4/26/2015)... April 26, 2015 This annual celebration ... the season and will include a spectacular collection of ... collectibles, herbal soaps and incense, chimes, vases, candleholders, fleece ... year’s exciting and unique collection of vendors, guests will ... Jim Martocci and the Jimmie Jazz Band. , ...
(Date:4/26/2015)... Hartford, CT (PRWEB) April 26, 2015 The ... welcome and reflection by Deb Dettor, CCAR’s Managing Director. Deb ... Phil Valentine who was not in attendance because of his ... To everyone’s delight, Phil was able to express his gratitude ... thanked the volunteers for their dedication to carrying out CCAR’s ...
(Date:4/25/2015)... ME (PRWEB) April 26, 2015 ... Canadian based integrative healthcare event. The Integrative Healthcare ... place October 23-24, 2015 at the Sheraton Parkway ... Symposium Canada is one of the most anticipated ... clinically relevant, evidenced-based CME program. The event aims ...
(Date:4/25/2015)... 2015 The Hon. Ellen Tauscher, Independent ... the following statement following the deadly earthquake in Nepal: ... resulting in the deaths of more than 1,000 people. ... across Nepal, Bangladesh, India and other parts of South ... to the people of Nepal and the families of ...
Breaking Medicine News(10 mins):Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 3Health News:It’s Coming! The 5th Annual Tulip Festival & Mother’s Day Celebration at Honor's Haven Resort & Spa! 2Health News:The Connecticut Community for Addiction Recovery (CCAR) honors its volunteers during National Volunteer Recognition Week. 2Health News:Integrative Healthcare Event launching in Canada 2
... participate in school-sponsored and club-level gymnastics competitions annually in ... in terms of potential for injury, while having one ... , A study, conducted by researchers in the Center ... Institute at Nationwide Childrens Hospital and published in the ...
... 4, 2008 Dialysis,Corporation of America (Nasdaq: DCAI ... its eleventh facility in that state., President & ... our growth in Pennsylvania, one of our core markets ... superior quality,care for the patients we are responsible for ...
... April 4, 2008 Companies align,commercial and portfolio ... an annual sales volume of $10 to 20 ... the early-stage commercialization team along,with approximately eight portfolio ... is approximately four to three, commercial to,portfolio management ...
... INDIANAPOLIS, April 4, 2008 Eli Lilly and ... European Commission has approved a new,indication for FORSTEO(R) ... associated with sustained, systemic,glucocorticoid therapy in women and ... the initial positive opinion issued in February by,the ...
... 2008 To promote,the U.S. Department of ... a,Healthy Future" initiative, Acting U.S. Surgeon General ... with several community leaders at A.I.,DuPont Hospital ... reducing,childhood obesity in Delaware., (Photo: httphttp://www.newscom.com/cgi-bin/prnh/20080403/18521), ...
... 2008 Targeted mass,media campaigns alone can ... young adults to adopt safer,sex practices, according ... of,Communication at the University of Kentucky with ... Past public health campaigns, particularly those ...
Cached Medicine News:Health News:Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania 2Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 3Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 4Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 5Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 2Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 3Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 2Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 3
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... international engineering and design specifications, Smith ... System* provides seamless integration with existing ... open reduction internal fixational procedures (AO ... well beyond the standard, providing a ...
... has been developed for the transvenous closure ... venous sheaths the device offers a safe ... of ASD's with a super low profile.,A ... twelve arm device for optimal positioning and ...
Stainless steel threaded Steinman Pins available in point types A,D, E, and F....
Medicine Products: